ESElena Georgievna Starostina

Elena Georgievna Starostina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elena Georgievna Starostina has a total of 135 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Characteristics of type 1 diabetic patients with psychoorganic syndrome

    by E. G. Starostina, T. S. Kotova, Е. Г. Старостина, Т. С. Котова

    BACKGROUND : The term “diabetic encephalopathy” or psychoorganic syndrome (POS) of diabetic origin) does not appear in current classifications of diabetic complications but is eventually used by researchers and physicians. However, evidence for its existence has been scarce and contradictory. AIM : To identify epidemiological, anamnestic, clinical and psychological characteristics of POS in young patients with T1DM and to assess its possible association with factors specific and non-specific for diabetes. METHODS : This single center, cross-sectional study consecutively enrolled T1DM in-patients aged 18 to 45 years with >1 year diabetes curation, without exclusion criteria (pregnancy, conditions hindering testing, and comorbidities that could cause organic brain damage). The clinical diagnosis of POS was made by a psychiatrist. In addition to clinical and laboratory examinations, cognitive functions (MMSE, Roshchina-Balashova-Korsakova scales, Wechsler, proofreading, and digit span tests) and emotional/personality characteristics (Multiple Minnesota Personality Inventory [MMPI] and CES-D depression scale) were assessed. In the univariate analysis, differences between patients with and without POS were tested with Mann-Whitney and χ2 tests. Multivariate regression analysis was performed to identify characteristics independently associated with POS. RESULTS : The study consecutively recruited 122 patients with T1DM (60 men) aged 18 to 40 years with diabetes duration of 1 to 27 years, age of onset 1 to 32 years, and glycated hemoglobin (HbA 1c ) level of 9.5±2.5% (range, 5.1 to 20.6%). POS was clinically diagnosed in 30 patients (24.6%). In the univariate analysis, patients with POS, compared to those without POS, were older, had higher prevalence of diabetic retinopathy, past history of severe hypoglycemia, arterial hypertension (AH), current depression, and a more pronounced decline in cognitive functions (mainly working memory, attention, visospatial skills, analysis and synthesis, generalization, and speed of task completion). There were no differences in sex ratio, age of onset and duration of diabetes, HbA 1c levels, and past history of diabetic ketoacidosis. Among the possible etiologies in the POS group compared to the non-POS group, severe infections (13.3 and 0%, p=0.003), prenatal injuries (60.7 and 43%, p=0.006), and controlled AH (33.3 and 13%, p=0.012) were more common. The biggest difference between-group was found for a combination of factors unrelated to diabetes (63.3 and 28.3%, p=0.001), especially brain trauma, alcohol abuse, perinatal injuries, severe infections, and AH. The multivariate analysis confirmed the significance of the combination of non-diabetic brain damaging factors in POS etiology (odds ratio [OR] 1.8, 95%CI 1.0–3.1, p=0.043), and revealed independent associations of POS with depression, diastolic blood pressure, and an inverse association with occupational mental complexity (OR 0.7, 95%CI 0.4–1.0, p=0.076). The multivariate regression did not confirm an independent association of POS with any of the potential diabetes-related factors of brain damage. CONCLUSION : The results obtained do not confirm the specific diabetic etiology of POS in T1DM and probably allow considering POS (encephalopathy) in patients with T1DM to be rather a multicausative comorbid condition of mostly exogenous origin.

  • Open Access

    Nutrition specifics in type 2 diabetic patients with binge eating disorder and the effects of glucagonlike peptide I receptor agonists

    by E. G. Starostina, M. V. Ananyan, Е. Г. Старостина, М. В. Ананян

    BACKGROUND: Binge eating disorder (BED) is the most prevalent eating disorder manifesting as episodes with higher than usual food intake uncontrolled by patients. Nutritional specifics, their associations with biological and psychological parameters in Type 2 diabetes mellitus (T2DM) with BED have not been studied. AIM: To identify specific characteristics of nutrition (food choices, food planning, diet barriers [DB]) in T2DM patients with and without BED, their associations with clinical, laboratory, and psychological parameters and their changes over time under treatment of BED. MATERIAL AND METHODS: T2DM patients with and without BED participated in this cross-sectional study. In those with and without BED, we compared the characteristics of nutritional style, clinical, laboratory and psychological parameters (depression, anxiety/anxiousness, some personality characteristics, including alexithymia, and diabetes-dependent quality of life (Qol). In subsequent prospective open-label interventional part of the study, we evaluated changes of the nutrition characteristics in T2DM patients with BED under treatment with glucagon-like peptide I receptor agonists (GLP1-RA) versus no BED treatment. The univariate analysis was performed at α=0,05, logistic regression at α=0,10. RESULTS: The study recruited 273 T2DM patients (176 with and 97 without BED). The BED patients ate less frequently than those without: minimal number of daily food intakes 2,6±1,1 and 2,9±0,8, respectively (р=0,010), food intake skipped 1,5±1,8 and 0,8±1,5 weekly (р=0,001). Compared to no-BED patients, those with BED consumed more sweets (р=0,003), “hidden” fats (eggs, р=0,015; nuts, р=0,027), and alcoholic drinks (р=0,004). In the BED group, there were 23 associations between various foods and clinical and laboratory parameters (9 of them indicated favorable and 14 unfavorable food effects). In the non-BED group, 6 associations were found, all them indicating favorable food effects. In both groups, the most significant DB was “difficult to withdraw sweets”. The BED-specific weighted DB were: “difficult to stick to a diet in unexpected situations”, “when I eat more than allowed, I feel bad”, “sometimes I am not allowed to eat being hungry”, and “I would like to eat foods that I should not eat”. Only in the BED group, there were weak but significant correlations between DB numbers/patient and metabolic parameters: НbA1c (r=0,210, р CONCLUSION: Specific characteristics of nutrition in T2DM patients with BED (less regular food intake, higher intake of unhealthy products and higher numbers of DB, compared to those in T2DM without BED) may negatively affect clinical, laboratory and psychological parameters. Three factors related to nutrition style are associated with increased BED risk and three, with lower risk. The results necessitate a personalized dietary approach to T2DM patients with BED, which requires its timely diagnosis made in primary and secondary care. GLP1-RAs exert no clinically valuable effects on the studied nutrition characteristics in BED patients with T2DM.

  • Hyperprolactinemia, Induced by Antipsychotics and Resistant to Cabergoline Therapy

    by O. A. Yunilaynen, E. G. Starostina, P. A. Baranov, I. V. Oleichik

    Background : hyperprolactinemia is common in patients with mental disorders receiving antipsychotics. Cabergoline therapy for normalizing prolactin in these patients has been found to be effective. Cases of prolactin-secreting pituitary adenomas resistant to cabergoline have been described in the literature. Clinical observations of antipsychotic-induced/antipsychoticassociated hyperprolactinemia resistant to cabergoline therapy are rare in scientific publications. The aim of the study was to describe clinical cases and justify treatment approaches to hyperprolactinemia, associated with antipsychotics and resistant to cabergoline therapy. Patients and Methods : the study involved female patients with endogenous mental disorders undergoing inpatient treatment. Clinical, psychopathological, and laboratory examination methods were used. Case description: Case 1 — a 23-year-old female, mentally ill since the age of 17, was twice treated in mental hospitals for a depressive state within the framework of schizotypal disorder. A severe course of depression with a high risk of suicide and clear resistance to drug therapy was noted; a course of ECT was administered. The therapeutic effect was achieved through the use of antipsychotics, but an increase in prolactin levels was detected. Hyperprolactinemia was accompanied by weight gain, lactorrhea, and hair loss. Cabergoline at a dose of 3.5 mg per week was ineffective. With the correction of antipsychotic therapy, the level of prolactin in the blood returned to normal. Case 2 — a 37-year-old female, mentally ill since the age of 19, was repeatedly treated in mental hospitals for hallucinatory-delusional symptoms. Chronicity of the disease and pronounced resistance to drug treatment were noted. A course of ECT was administered to overcome resistance. Prescription of antipsychotics resulted in a significant reduction in hallucinatory-delusional symptoms and improvement in the patient's quality of life; however, the development of hyperprolactinemia was detected. Cabergoline at a dose of 3.5 mg per week was ineffective. Hyperprolactinemia was virtually asymptomatic (including the absence of hypogonadism), cabergoline was terminated, and psychopharmacotherapy was continued according to the previous treatment regimen. Conclusion : if cabergoline 3.0 mg/week is ineffective, antipsychotic-induced/ antipsychotic-associated hyperprolactinemia may be considered cabergoline-resistant. The choice of treatment tactics in this case should be carried out individually, taking into account the clinical manifestations of hyperprolactinemia, a comprehensive analysis of laboratory parameters, and the specificities of the course of the mental disorder.

  • Efficacy and safety of glucagon-like peptide-1 receptor agonists in the treatment of binge eating disorder in Type 2 diabetic patients: a pilot study in real world clinical practice

    by E. G. Starostina, M. V. Ananyan

    BACKGROUND : Binge eating disorder (BED) is the most prevalent eating disorder in the population, poorly studied in patients with Type 2 diabetes mellitus (T2DM). There are no generally accepted guidelines on pharmacological treatment of BED and no studies with more than 3-month duration. Glucagon-like peptide 1 receptor agonists (GLP1RA) could be a promising class of agents for the treatment of BED in T2DM patients due to their effects on central mechanisms of appetite and satiety regulation. AIM : To assess efficacy and safety of GLP1 RA for treatment of BED in patients with T2D. METHODS : Sixty six outpatients with T2DM and BED participated in this pilot open-label prospective comparative study of 6 mo’ duration followed by a 6 mo follow-up after GLP1RA withdrawal. All 66 continued their previous anti-hyperglycemic agents, 33 patients (50%) were prescribed a GLPRA (dulaglutide, or semaglutide, or lixisenatide combined with glargin). ­Thirty three patients were in the control group without GLPRA. In addition to standard clinical and laboratory examinations, all patients completed tests/questionnaires for assessment of their quality of life, depression, stait/trait anxiety, alexithymia and other personality characteristics, and physical complaints. Changes in BED severity and all other parameters were assessed at 3 and 6 months, and BED severity only was assessed at 6 months after the end of GLP1RA. RESULTS : After 6 months of GLP1RA therapy, 63,6% of the patients were in complete remission of BED (рCONCLUSION : GLP1 receptor agonists are effective, safe and well tolerated in the treatment of BED in Type 2 diabetes patients. They facilitate the achievement of the main goal of BED treatment (complete or partial remission of BED) in 100% of the cases with marked improvements in metabolic and a range of psychological parameters.


  • Open Access

    Psychoorganic syndrome in type 1 diabetes mellitus: a concomitant disease or a complication of diabetes? (Review)

    by E. G. Starostina, T. S. Kotova

    Psychoorganic syndrome (POS), also known as organic brain syndrome, or encephalopathy, is characterized by cognitive decline, emotional incontinence (emotional lability), and asthenic symptoms. It can develop due to a number of exogenous and endogenous factors, and despite the use of the term «diabetic encephalopathy», the evidence for a specific diabetic etiology of POS remains limited. The review provides a detailed history of the term POS and its definition, components and possible causes, pros and cons of the existence of POS of diabetic origin. The potential influence of dysglycemia on the development of POS and brain abnormalities in Type 1 diabetic patients (T1D) found at neuroimaging, as well as their associations between each other and with other clinical parameters, including the age at diabetes manifestation, disease duration, acute diabetic complications, and diabetic retinopathy as a marker of a long-term exposure to hyperglycemia, are discussed. In young adults with T1DM, cognitive function parameters fall within the age-related reference ranges, and their associations with the degree of hyperglycemia or severe hypoglycemia are not reproducible in larger samples. The analysis of neuroimaging and histological data also does not provide convincing evidence that brain abnormalities are unique to T1DM. Thus, the issue of POS (encephalopathy) in T1DM remains insufficiently studied and controversial. Current data does not allow to unequivocally accept the specific diabetic nature of POS/encephalopathy in T1D. Further studies are necessary to identify the contribution of diabetes and associated factors to the development of POS, including histological data.


  • Association of cortisol levels with psychopathological features of depression and therapeutic response in female patients

    by O.A. Yunilainen, E.G. Starostina, P.A. Baranov, S.A. Zozulya, I.N. Otman, E.G. Przhiyalkovskaya, I.V. Oleichik, Yu.A. Chaika

    Objective. To study the association of cortisol level, clinical features of depression, its nosological type, and the therapeutic response in female patients. Material and methods. 69 females aged 18 to 50 were examined; clinical-psychopathological, clinical-prospective, psychometric, laboratory, and statistical methods were used. Results. 17 patients were included in the group with depression without signs of resistance, and 52 in the group of therapeutically resistant depression (TRD). Hypercortisolemia at baseline was observed in 23% of patients, and hypocortisolemia in 6%. The absence of cortisol inhibition in a low-dose dexamethasone suppression test (LDDST) was found in 42% of patients. Patients with hypercortisolemia were more likely to be diagnosed with paroxysmal schizophrenia compared to patients with normal cortisol: 3/16 (19%) vs. 1/49 (2%), respectively (p=0.043). There were no differences in the clinical and psychopathological structure of depression and its formal severity in patients with hypercortisolemia and normal cortisol levels. In psychometric assessment, patients with hypercortisolemia had significantly higher scores of psychomotor retardation (HAMD, case report form) than those with normal cortisol levels (p=0.009). In the group with negative LDDST, significantly higher agitation (p=0.045) and adynamia (p=0.017) scores were found than those with positive LDDST. In patients with abnormal circadian rhythm of cortisol secretion, significantly higher anhedonia scores were noted than in patients with normal daily cortisol secretion (p=0.02). The state of patients with negative LDDST was significantly worse at follow-up examination than in those with positive LDDST (p=0.04). In patients with a good response to treatment, the cortisol level in LDDST upon repeated examination was significantly lower than in non-curable patients: 34.1 [22.8—65.3] and 80.2 [66.8—120.8] nmol/L, respectively (p=0.02). Conclusions. In patients with depression, the prevalence of hypothalamic-pituitary-adrenal (HPA) axis dysfunction is higher than in the general population. HPA axis dysfunction appears to be associated with psychomotor retardation, adynamia, agitation, and anhedonia. The lack of cortisol inhibition in LDDST is the most reliable laboratory marker of a low-curable depressive state. Absolute treatment resistance in depression is associated with HPA axis dysfunction.


  • Functional hypercortisolism in mental disorder — association with psychopathological manifestations and course of the disease

    by O.A. Yunilaynen, P.A. Baranov, E.G. Starostina, E.G. Przhiyalkovskaya, S.A. Zozulya, I.N. Ottman, I.V. Oleychik

    The article presents a case of a long-term mental disorder in a 35-year-old woman with a persistent laboratory-confirmed increase in cortisol levels, without clinical manifestations of hypercortisolism. The first signs of mental illness appeared at the age of 14; over the past 8 years, the disease has been continuous and manifests itself in the form of a predominantly depressive state with increasing severity and complication of symptoms. Throughout all the years of the disease, active psychopharmacotherapy was carried out, combinations of antidepressants with antipsychotics and mood stabilizers were used, but no pronounced effect was achieved. Inpatient treatment in the clinic of the Mental Health Research Center for 5 months using several methods of enhancing antidepressant therapy had a good therapeutic effect and made it possible to achieve complete remission of the disease. There was a normalization of laboratory parameters of cortisol along with a decrease in the severity of pathopsychological symptoms, which indicates the genesis of hypercortisolism secondary to mental illness and its functional nature. It is assumed that hypercortisolism in this patient contributed to the formation of atypical clinical symptoms and resistance to antidepressant therapy. The discussion substantiates the need to consult a psychiatrist in case of persistent hypercortisolism in the absence of clinical manifestations of Cushing’s syndrome. The detection of persistent hypercortisolism in patients with depression determines the advisability of active therapy using several tactics to enhance the effect of antidepressants.

  • Open Access

    Binge eating disorder: epidemiological, clinical, pathophysiological, and treatment aspects

    by E. G. Starostina, M. V. Ananyan

    Binge eating disorder (BED) is the most prevalent type of eating disorders encountered in endocrinological practice, with 5 to 66% of obesity patients seeking for losing weight, 10 to 25% of patients with Type 2 diabetes mellitus, and above 70% of Type 2 patients with morbid obesity having BED. BED can seriously challenge the treatment for Type 2 diabetes and obesity, but remains underdiagnosed and undertreated in most cases. The review discussed diagnostic criteria of BED and their evolution during the last three decades, as well as neurochemical, genetic, and psychological components of its pathophysiology and potential role of BED as a new risk factor for Type 2 diabetes. We have also analyzed medical treatments available for an endocrinologist, including potential use of agonists of glucagone-like peptide 1 receptors.


  • Top Cited Papers
    Open Access

    Standards of Specialized Diabetes Care / Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 11th Edition

    by Иван Иванович Дедов, Марина Владимировна Шестакова, A. Mayorov, Наталья Георгиевна Мокрышева, Елена Николаевна Андреева, Ольга Борисовна Безлепкина, Валентина Александровна Петеркова, Екатерина Викторовна Артемова, P. Bardiugov, Диана Джемаловна Бешлиева, et al.

    Dear Colleagues!We are glad to present the 11th Edition of the Standards of Specialized Diabetes Care. These evidence-based guidelines were designed to standardize and facilitate diabetes care in all regions of the Russian Federation.The Standards are updated on the regular basis to incorporate new data and relevant recommendations from national and international clinical societies, including World Health Organization Guidelines (WHO), International Diabetes Federation (IDF), European Association for the Study of Diabetes (EASD), American Diabetes Association (ADA), American Association of Clinical Endocrinologists (AACE), International Society for Pediatric and Adolescent Diabetes (ISPAD) and Russian Association of Endocrinologists (RAE). Current edition of the “Standards” also integrates results of completed randomized clinical trials, as well as findings from the national studies of diabetes mellitus (DM), conducted in close partnership with a number of Russian hospitals.Latest data indicates that prevalence of DM in the world increased during the last decade more than two-fold, reaching some 537 million patients by the end of 2021. According to the current estimation by the International Diabetes Federation, 643 million patients will be suffering from DM by 2030 and 783 million by 2045.Like many other countries, Russian Federation experiences a sharp rise in the prevalence of DM. According to Russian Federal Diabetes Register, there are at least 4 962 762 patients with DM in this country on 01.01.2023 (3,42% of population) with 92,3% (4 581 990) – Type 2 DM, 5,6% (277 092) – Type 1 DM and 2,1% (103 680) – other types of DM, including 8 758 women with gestational DM. However, these results underestimate real quantity of patients, because they consider only registered cases. Results of Russian epidemiological study (NATION) confirmed that 54% of patients with Type 2 DM are undiagnosed. So real number of patients with DM in Russia is 11-12 million patients (about 7% of population). This is a great long-term problem, because a lot of patients are not diagnosed, so they don’t receive any treatment and have high risk of vascular complications.Severe consequences of the global pandemic of DM include its vascular complications: nephropathy, retinopathy, coronary, cerebral and peripheral vascular disease. These conditions are responsible for the majority of cases of diabetes-related disability and death.In accordance with the Federal Law № 489-FZ of 25.12.2018 medical care should be provided on the basis of the clinical recommendations. Therefore, clinical recommendations posted in the rubricator of the Ministry of Health of the Russian Federation (https://cr.minzdrav.gov.ru) being the priority.This edition of the Algorithms for Specialized Care for Patients with Diabetes Mellitus contains the main information from the clinical guidelines for the management of diabetes mellitus in adults and children (“Type 1 Diabetes in Children (2022)”, “Type 1 Diabetes in Adults (2022)”, “Type 2 diabetes mellitus in children (2021)”, “Type 2 diabetes mellitus in adults (2022)”), as well as the updated data.New information has been added about indications for using of antihyperglycemic drugs and their instructional restrictions; algorithm of treatment of type 2 diabetes mellitus has been updated; clarifications have been made on the range of glycemic control in pregnant women; information on the treatment of diabetic complications and the management of pediatric patients has been added. In 2023, Russian diabetology suffered an unbearable loss - Alexander Yuryevich Mayorov, who was the executive editor of the previous issues and an active participant of the work on all the previous editions of “Algorithms” from the moment they were founded, passed away. This publication is dedicated to the memory of Alexander Yuryevich, who was an example of the service to patients and medicine, a friend, teacher, mentor, generously sharing his knowledge and the sample of the execution of the medical duty to all of us. On behalf of the Working Group


  • Open Access

    Hypothalamo-Pituitary-Adrenal Axis in Depressive Disorders and Treatment Resistance

    by O. A. Yunilayne, E. G. Starostina, I. V. Oleichik

    Background: hypothalamo-pituitary-adrenal (HPA) axis plays an important role in the pathogenesis of depression. Patterns of HPA functioning depend on both biologic factors and psychological background, which, taken together, may increase the risk of depression later on. Objective: to analyze scientific publications on pathophysiology of depression, linked to HPA disruption, assess causal relationship between hypercorticism and depression, role of hypercorticism in clinical symptoms and course of depressive disorder.Material and methods: according to the key words “hypercortiсism”, “depression disorder”, “cortisol”, “treatment resistant depression”, “Cushing’s syndrome”, “Сushing’s disease”, a search was conducted for publications in databases Medline/ PubMed, Scopus, Web of Science, RSCI and other resources.Conclusion: there is a high comorbidity between depressive disorders and HPA axis abnormalities, including endocrine disorders with both increased and decreased cortisol secretion. Hypercorticism related to Сushing’s disease or Cushing’s syndrome is often associated with irreversible mental disorders, especially anxiety and depressive disorders, which persist after normalization of cortisol levels. Depressive patients are characterized by persistently elevated cortisol levels and their non-supression in the 1 mg dexamethasone suppression test (DST); however, sometimes they have reduced cortisol secretion. The possible pathophysiology mechanisms of hypercorticism are discussed. Beside hypercorticism, increased level of adrenocorticotropic hormone (ACTH) and decreased secretion of ACTH after CRH stimulation are demonstrated. It has been demonstrated that elevation of cortisol levels may precede the development of depression and as such can be used as marker of increased depression risk. Hypercorticism in patients with depression may promote its increased severity and transform ation of depressive symptoms. Persistent hypercorticism and non-supression of cortisol in DST are predictors of poor outcomes. HPA dysfunction seems to play an essential role in evolvement of treatment resistant depression. There is data on the efficacy of drugs modifying HPA activity for amelioration of affective disorders and psychotic symptoms in patients with depression. Further research into HPA functioning in patients with depression are needed to clarify pathogenetic mechanisms and development of newer treatment approaches to depression.